Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1989 2
1991 2
1992 2
1993 3
1994 5
1995 1
1996 7
1997 5
1998 9
1999 7
2000 3
2001 5
2002 4
2003 8
2004 5
2005 5
2006 7
2007 4
2008 12
2009 5
2010 6
2011 6
2012 6
2013 1
2015 2
2016 1
2017 1
2018 2
2020 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Results by year

Filters applied: . Clear all
Page 1
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Burris HA 3rd, et al. Among authors: rothenberg ml. J Clin Oncol. 1997 Jun;15(6):2403-13. doi: 10.1200/JCO.1997.15.6.2403. J Clin Oncol. 1997. PMID: 9196156 Corrected and republished. Clinical Trial.
New anticancer agents.
Weiss GR, Burris HA 3rd, Eckardt JR, Fields S, O'Rourke T, Rodriguez GI, Rothenberg ML. Weiss GR, et al. Among authors: rothenberg ml. Cancer Chemother Biol Response Modif. 1994;15:130-51. Cancer Chemother Biol Response Modif. 1994. PMID: 7779583 Review. No abstract available.
Accelerating anticancer drug development - opportunities and trade-offs.
Nass SJ, Rothenberg ML, Pentz R, Hricak H, Abernethy A, Anderson K, Gee AW, Harvey RD, Piantadosi S, Bertagnolli MM, Schrag D, Schilsky RL. Nass SJ, et al. Among authors: rothenberg ml. Nat Rev Clin Oncol. 2018 Dec;15(12):777-786. doi: 10.1038/s41571-018-0102-3. Nat Rev Clin Oncol. 2018. PMID: 30275514 Review.
Alternative dosing schedules for irinotecan.
Rothenberg ML, Kuhn JG, Schaaf LJ, Drengler RL, Eckhardt SG, Villalona-Calero MA, Hammond L, Miller LL, Petit RG, Rowinsky EK, Von Hoff DD. Rothenberg ML, et al. Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):68-71. Oncology (Williston Park). 1998. PMID: 9726095 Review.
Mechanisms of resistance to cisplatin and alkylating agents.
Hamilton TC, Lai GM, Rothenberg ML, Fojo AT, Young RC, Ozols RF. Hamilton TC, et al. Among authors: rothenberg ml. Cancer Treat Res. 1989;48:151-69. doi: 10.1007/978-1-4613-1601-5_10. Cancer Treat Res. 1989. PMID: 2577136 Review. No abstract available.
The continuum of care: a paradigm for the management of metastatic colorectal cancer.
Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB 3rd, Blanke CD, Diasio RB, Grothey A, Lenz HJ, Meropol NJ, Ramanathan RK, Becerra CH, Wickham R, Armstrong D, Viele C. Goldberg RM, et al. Among authors: rothenberg ml. Oncologist. 2007 Jan;12(1):38-50. doi: 10.1634/theoncologist.12-1-38. Oncologist. 2007. PMID: 17227899 Free article. Review.
122 results